GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Cyclically Adjusted Price-to-FCF

NeoGenomics (STU:NG9) Cyclically Adjusted Price-to-FCF : (As of Dec. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for NeoGenomics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Cyclically Adjusted Price-to-FCF Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 484.39 1,172.56 - - -

NeoGenomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeoGenomics's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted Price-to-FCF falls into.



NeoGenomics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

NeoGenomics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, NeoGenomics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.011/133.0289*133.0289
=-0.011

Current CPI (Sep. 2024) = 133.0289.

NeoGenomics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.001 99.070 -0.001
201503 -0.025 99.621 -0.033
201506 0.035 100.684 0.046
201509 0.028 100.392 0.037
201512 0.024 99.792 0.032
201603 0.072 100.470 0.095
201606 0.030 101.688 0.039
201609 0.088 101.861 0.115
201612 -0.030 101.863 -0.039
201703 -0.056 102.862 -0.072
201706 0.019 103.349 0.024
201709 0.054 104.136 0.069
201712 0.024 104.011 0.031
201803 0.097 105.290 0.123
201806 0.022 106.317 0.028
201809 0.059 106.507 0.074
201812 0.111 105.998 0.139
201903 0.027 107.251 0.033
201906 -0.071 108.070 -0.087
201909 0.095 108.329 0.117
201912 -0.023 108.420 -0.028
202003 -0.101 108.902 -0.123
202006 -0.026 108.767 -0.032
202009 -0.052 109.815 -0.063
202012 -0.036 109.897 -0.044
202103 -0.098 111.754 -0.117
202106 -0.144 114.631 -0.167
202109 -0.158 115.734 -0.182
202112 -0.229 117.630 -0.259
202203 -0.274 121.301 -0.300
202206 -0.208 125.017 -0.221
202209 -0.196 125.227 -0.208
202212 -0.062 125.222 -0.066
202303 -0.169 127.348 -0.177
202306 -0.067 128.729 -0.069
202309 -0.073 129.860 -0.075
202312 0.078 129.419 0.080
202403 -0.230 131.776 -0.232
202406 0.006 132.554 0.006
202409 -0.011 133.029 -0.011

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (STU:NG9) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


NeoGenomics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

NeoGenomics Headlines

No Headlines